Efrain Santiago PharmD, MBA Disclaimer This information is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment
Hedberg et al
Beginning July 1, 2026, the Medicare GLP-1 Bridge will cover select medications including Foundayo, Wegovy and Zepbound KwikPen for eligible Part D participants
Semaglutide has one of the most extensive clinical trial programs in metabolic research, including the SUSTAIN series (diabetes), STEP program (obesity), PIONEER trials (oral formulation), and SELECT trial (cardiovascular outcomes)
That's not a reason to assume it won't do anything for you
Treatment may be discontinued in patients who do not achieve an early virological response at 12 weeks, although the decision should be individualized according to the tolerability of therapy, severity of underlying liver disease and demonstration of some degree of biochemical and/or virological response (I, III) 14